AbbVie Inc. (ABBV) holds a prominent place in our 110-stock watchlist. As of May 27, 2026, we examine the consensus metrics.
What the data shows
ABBV trades at $213.12 with a mean target price of $252.90, suggesting an 18.7% upside. Twenty-nine analysts cover the stock. It carries a 13.13 forward P/E, a 3.21% dividend yield, and a 0.305 beta. Recent price target shifts include Piper Sandler raising its target to $298 on May 14, while Evercore ISI Group adjusted its target to $235 on May 15.
| Metric | Value |
|---|---|
| Current Price | $213.12 |
| Mean Target | $252.90 |
| Upside | 18.7% |
| Analysts | 29 |
How to read these figures
Upside represents the percentage difference between the current price and the average analyst target. A "buy" consensus reflects the majority sentiment among tracked firms. Note that targets are forward-looking opinions, not guarantees.
ABBV in context
Within the healthcare sector, ABBV ranks 4th in upside potential. Its 18.7% figure sits near the 19% sector average. Peers like DHR (43.4%) and TMO (36.5%) show higher consensus expectations. Learn more about ABBV methodology.
Key takeaways
* Consensus implies a potential 18.7% price appreciation. * Analyst sentiment remains split, with recent target adjustments. * Insider activity shows 10 meaningful sales and zero buys.
Frequently asked questions
What is the consensus target?
It is the arithmetic mean of price targets issued by the 29 analysts currently covering AbbVie.
What does the upside percentage mean?
It measures the expected growth from the current market price to the average analyst target over their forecast horizon.